Therapeutic potential of metabotropic glutamate receptor modulators

Current Neuropharmacology

Volumn 10, Issue 1, 2012, Pages 12-48

  Hovelso N ^a   Sotty, F ^a   Montezinho, L P ^a   Pinheiro, P S ^b   Herrik, K F ^a   Mork A ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Addiction; Alzheimer's disease; Anxiety; Depression; Epilepsy; Fragile X syndrome; Huntington's disease; Metabotropic glutamate receptors; Pain; Parkinson's disease; Schizophrenia

Indexed keywords

(4 FLUOROPHENYL) [3 [3 (4 FLUOROPHENYL) [1,2,4] OXADIAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; 1 [2 HYDROXY 3 METHYL 4 [4 [4 (2H TETRAZOL 5 YL)PHENOXY]BUTOXY]PHENYL]ETHANONE; 1 AMINO 1,5 INDANDICARBOXYLIC ACID; 1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 2 (3 CARBOXYCYCLOBUTYL) 3 (9 THIOXANTHYL)PROPIONIC ACID; 2 AMINO 2 (4 CARBOXYPHENYL) 3 (9 THIOXANTHYL)PROPIONIC ACID; 2 AMINO 4 PHOSPHONOBUTYRIC ACID; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 3,5 DIHYDROXYPHENYLGLYCINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 4 CARBOXYPHENYLGLYCINE; 4 PHOSPHONOPHENYLGLYCINE; 6A NAPHTALEN 2 YL METHYL 5 METHYLIDEN HEXAHYDROCYCLOPENTAL[C]FURAN 1 ON]; 9 DIMETHYLAMINO 3 (4 ETHYLPHENYL) 3H 5 THIA 1,3,6 TRIAZAFLUOREN 4 ONE; 9 DIMETHYLAMINO 3 (4 METHYLPHENYL) 3H 5 THIA 1,3,7 TRIAZAFLUOREN 4 ONE; 9 DIMETHYLAMINO 3 (N HEXAMETHYLENEIMINYL) 3H 5 THIA 1,3,6 TRIAZAFLUOREN 4 ONE; 9 DIMETHYLAMINO 3 CYCLOHEPTYL 3H 5 THIA 1,3,6 TRIAZAFLUOREN 4 ONE; A 794278; A 794282; A 841720; A 850002; BIPHENYLINDANONE A; EGLUMETAD; GLUTAMATE CARBOXYPEPTIDASE II; LY 339764; LY 339840; LY 367335; LY 456066; LY 456236; LY 487379; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; N,N' DIBENZHYDRYLETHANE 1,2 DIAMINE DIHYDROCHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; COCAINE DEPENDENCE; DRUG DEPENDENCE; DRUG MECHANISM; FRAGILE X SYNDROME; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; LONG TERM DEPRESSION; MAJOR DEPRESSION; NERVE CELL; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SPINAL CORD; THERAPY EFFECT;

EID: 84857705629     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912799362805     Document Type: Review

References (406)

1. Conn, P. J.; Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 205-237.
2. Pin, J. P.; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995, 34 (1), 1-26.
3. De Vry, J.; Horvath, E.; Schreiber, R. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur. J. Pharmacol., 2001, 428 (2), 203-214.
4. Masu, M.; Tanabe, Y.; Tsuchida, K.; Shigemoto, R.; Nakanishi, S. Sequence and expression of a metabotropic glutamate receptor. Nature, 1991, 349 (6312), 760-765.
5. Abe, T.; Sugihara, H.; Nawa, H.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J. Biol. Chem., 1992, 267 (19), 13361-13368.
6. Kew, J. N.; Kemp, J. A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl), 2005, 179 (1), 4-29.
7. Martin, L. J.; Blackstone, C. D.; Huganir, R. L.; Price, D. L. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron, 1992, 9 (2), 259-270.
8. Fotuhi, M.; Sharp, A. H.; Glatt, C. E.; Hwang, P. M.; von, K. M.; Snyder, S. H.; Dawson, T. M. Differential localization of phosphoinositide- linked metabotropic glutamate receptor (mGluR1) and the inositol 1,4,5-trisphosphate receptor in rat brain. J. Neurosci., 1993, 13 (5), 2001-2012.
9. Lujan, R.; Nusser, Z.; Roberts, J. D.; Shigemoto, R.; Somogyi, P. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci., 1996, 8 (7), 1488-1500.
10. Shigemoto, R.; Nomura, S.; Ohishi, H.; Sugihara, H.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett., 1993, 163 (1), 53-57.
11. Rodrigues, R. J.; Alfaro, T. M.; Rebola, N.; Oliveira, C. R.; Cunha, R. A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem., 2005, 92 (3), 433-441.
12. Romano, C.; Sesma, M. A.; McDonald, C. T.; O'Malley, K.; Van den Pol, A. N.; Olney, J. W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol., 1995, 355 (3), 455-469.
13. Lujan, R.; Roberts, J. D.; Shigemoto, R.; Ohishi, H.; Somogyi, P. Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. J. Chem. Neuroanat., 1997, 13 (4), 219-241.
14. Ferraguti, F.; Shigemoto, R. Metabotropic glutamate receptors. Cell Tissue Res., 2006, 326 (2), 483-504.
15. Petralia, R. S.; Wang, Y. X.; Niedzielski, A. S.; Wenthold, R. J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience, 1996, 71 (4), 949-976.
16. Shigemoto, R.; Kinoshita, A.; Wada, E.; Nomura, S.; Ohishi, H.; Takada, M.; Flor, P. J.; Neki, A.; Abe, T.; Nakanishi, S.; Mizuno, N. Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus. J. Neurosci., 1997, 17 (19), 7503-7522.
17. Tamaru, Y.; Nomura, S.; Mizuno, N.; Shigemoto, R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience, 2001, 106 (3), 481-503.
18. Hayashi, Y.; Momiyama, A.; Takahashi, T.; Ohishi, H.; Ogawa-Meguro, R.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb. Nature, 1993, 366 (6456), 687-690.
19. Neki, A.; Ohishi, H.; Kaneko, T.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody. Neurosci. Lett., 1996, 202 (3), 197-200.
20. Neki, A.; Ohishi, H.; Kaneko, T.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Metabotropic glutamate receptors mGluR2 and mGluR5 are expressed in two non-overlapping populations of Golgi cells in the rat cerebellum. Neuroscience, 1996, 75 (3), 815-826.
21. Ohishi, H.; Akazawa, C.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Distributions of the mRNAs for L-2-amino-4-phosphonobutyratesensitive metabotropic glutamate receptors, mGluR4 and mGluR7, in the rat brain. J. Comp. Neurol., 1995, 360 (4), 555-570.
22. Ohishi, H.; Ogawa-Meguro, R.; Shigemoto, R.; Kaneko, T.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron, 1994, 13 (1), 55-66.
23. Nakajima, Y.; Iwakabe, H.; Akazawa, C.; Nawa, H.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J. Biol. Chem., 1993, 268 (16), 11868-11873.
24. Glaum, S. R.; Miller, R. J. Metabotropic glutamate receptors depress afferent excitatory transmission in the rat nucleus tractus solitarii. J. Neurophysiol., 1993, 70 (6), 2669-2672.
25. Dalezios, Y.; Lujan, R.; Shigemoto, R.; Roberts, J. D.; Somogyi, P. Enrichment of mGluR7a in the presynaptic active zones of GABAergic and non-GABAergic terminals on interneurons in the rat somatosensory cortex. Cereb. Cortex, 2002, 12 (9), 961-974.
26. Somogyi, P.; Dalezios, Y.; Lujan, R.; Roberts, J. D.; Watanabe, M.; Shigemoto, R. High level of mGluR7 in the presynaptic active zones of select populations of GABAergic terminals innervating interneurons in the rat hippocampus. Eur. J. Neurosci., 2003, 17 (12), 2503-2520.
27. Azkue, J. J.; Murga, M.; Fernandez-Capetillo, O.; Mateos, J. M.; Elezgarai, I.; Benitez, R.; Osorio, A.; Diez, J.; Puente, N.; Bilbao, A.; Bidaurrazaga, A.; Kuhn, R.; Grandes, P. Immunoreactivity for the group III metabotropic glutamate receptor subtype mGluR4a in the superficial laminae of the rat spinal dorsal horn. J. Comp. Neurol., 2001, 430 (4), 448-457.
28. Jia, H.; Rustioni, A.; Valtschanoff, J. G. Metabotropic glutamate receptors in superficial laminae of the rat dorsal horn. J. Comp. Neurol., 1999, 410 (4), 627-642.
29. Kinzie, J. M.; Saugstad, J. A.; Westbrook, G. L.; Segerson, T. P. Distribution of metabotropic glutamate receptor 7 messenger RNA in the developing and adult rat brain. Neuroscience, 1995, 69 (1), 167-176.
30. Li, H.; Ohishi, H.; Kinoshita, A.; Shigemoto, R.; Nomura, S.; Mizuno, N. Localization of a metabotropic glutamate receptor, mGluR7, in axon terminals of presumed nociceptive, primary afferent fibers in the superficial layers of the spinal dorsal horn: an electron microscope study in the rat. Neurosci. Lett., 1997, 223 (3), 153-156.
31. Ohishi, H.; Nomura, S.; Ding, Y. Q.; Shigemoto, R.; Wada, E.; Kinoshita, A.; Li, J. L.; Neki, A.; Nakanishi, S.; Mizuno, N. Presynaptic localization of a metabotropic glutamate receptor, mGluR7, in the primary afferent neurons: an immunohistochemical study in the rat. Neurosci. Lett., 1995, 202 (1-2), 85-88.
32. Bhave, G.; Karim, F.; Carlton, S. M.; Gereau, R. W. Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat. Neurosci., 2001, 4 (4), 417-423.
33. Carlton, S. M.; Hargett, G. L. Colocalization of metabotropic glutamate receptors in rat dorsal root ganglion cells. J. Comp. Neurol., 2007, 501 (5), 780-789.
34. Walker, K.; Reeve, A.; Bowes, M.; Winter, J.; Wotherspoon, G.; Davis, A.; Schmid, P.; Gasparini, F.; Kuhn, R.; Urban, L. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology, 2001, 40 (1), 10-19.
35. Taylor, D. L.; Jones, F.; Kubota, E. S.; Pocock, J. M. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J. Neurosci., 2005, 25 (11), 2952-2964.
36. Taylor, D. L.; Diemel, L. T.; Cuzner, M. L.; Pocock, J. M. Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J. Neurochem. 2002, 82 (5), 1179-1191.
37. Deng, W.; Wang, H.; Rosenberg, P. A.; Volpe, J. J.; Jensen, F. E. Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc. Natl. Acad. Sci. USA, 2004, 101 (20), 7751-7756.
38. Muyderman, H.; Angehagen, M.; Sandberg, M.; Bjorklund, U.; Olsson, T.; Hansson, E.; Nilsson, M. Alpha 1-adrenergic modulation of metabotropic glutamate receptor-induced calcium oscillations and glutamate release in astrocytes. J. Biol. Chem., 2001, 276 (49), 46504-46514.
39. Aronica, E.; Gorter, J. A.; Ijlst-Keizers, H.; Rozemuller, A. J.; Yankaya, B.; Leenstra, S.; Troost, D. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur. J. Neurosci., 2003, 17 (10), 2106-2118.
40. Aronica, E.; Gorter, J. A.; Rozemuller, A. J.; Yankaya, B.; Troost, D. Activation of metabotropic glutamate receptor 3 enhances interleukin (IL)-1beta-stimulated release of IL-6 in cultured human astrocytes. Neuroscience, 2005, 130 (4), 927-933.
41. Glaum, S. R.; Miller, R. J. Metabotropic glutamate receptors mediate excitatory transmission in the nucleus of the solitary tract. J. Neurosci., 1992, 12 (6), 2251-2258.
42. Anwyl, R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res. Brain Res. Rev., 1999, 29 (1), 83-120.
43. Pinheiro, P. S.; Mulle, C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat. Rev. Neurosci., 2008, 9 (6), 423-436.
44. Barrie, A. P.; Nicholls, D. G.; Sanchez-Prieto, J.; Sihra, T. S. An ion channel locus for the protein kinase C potentiation of transmitter glutamate release from guinea pig cerebrocortical synaptosomes. J. Neurochem., 1991, 57 (4), 1398-1404.
45. Coffey, E. T.; Herrero, I.; Sihra, T. S.; Sanchez-Prieto, J.; Nicholls, D. G. Glutamate exocytosis and MARCKS phosphorylation are enhanced by a metabotropic glutamate receptor coupled to a protein kinase C synergistically activated by diacylglycerol and arachidonic acid. J. Neurochem., 1994, 63 (4), 1303-1310.
46. Wang, S. J.; Sihra, T. S. Noncompetitive metabotropic glutamate5 receptor antagonist (E)-2-methyl-6-styryl-pyridine (SIB1893) depresses glutamate release through inhibition of voltage-dependent Ca2+ entry in rat cerebrocortical nerve terminals (synaptosomes). J. Pharmacol. Exp. Ther., 2004, 309 (3), 951-958.
47. Sanchez-Prieto, J.; Paternain, A. V.; Lerma, J. Dual signaling by mGluR5a results in bi-directional modulation of N-type Ca2+ channels. FEBS Lett., 2004, 576 (3), 428-432.
48. Kreitzer, A. C.; Regehr, W. G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 2001, 29 (3), 717-727.
49. Pelkey, K. A.; Topolnik, L.; Lacaille, J. C.; McBain, C. J. Compartmentalized Ca(2+) channel regulation at divergent mossy-fiber release sites underlies target cell-dependent plasticity. Neuron, 2006, 52 (3), 497-510.
50. Robbe, D.; Alonso, G.; Chaumont, S.; Bockaert, J.; Manzoni, O. J. Role of p/q-Ca2+ channels in metabotropic glutamate receptor 2/3- dependent presynaptic long-term depression at nucleus accumbens synapses. J. Neurosci., 2002, 22 (11), 4346-4356.
51. O'Connor, V.; El, F. O.; Bofill-Cardona, E.; Nanoff, C.; Freissmuth, M.; Karschin, A.; Airas, J. M.; Betz, H.; Boehm, S. Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling. Science, 1999, 286 (5442), 1180-1184.
52. Pelkey, K. A.; Lavezzari, G.; Racca, C.; Roche, K. W.; McBain, C. J. mGluR7 is a metaplastic switch controlling bidirectional plasticity of feedforward inhibition. Neuron, 2005, 46 (1), 89-102.
53. Perroy, J.; Prezeau, L.; De, W. M.; Shigemoto, R.; Bockaert, J.; Fagni, L. Selective blockade of P/Q-type calcium channels by the metabotropic glutamate receptor type 7 involves a phospholipase C pathway in neurons. J. Neurosci., 2000, 20 (21), 7896-7904.
54. Blackmer, T.; Larsen, E. C.; Takahashi, M.; Martin, T. F.; Alford, S.; Hamm, H. E. G protein betagamma subunit-mediated presynaptic inhibition: regulation of exocytotic fusion downstream of Ca2+ entry. Science, 2001, 292 (5515), 293-297.
55. Blackmer, T.; Larsen, E. C.; Bartleson, C.; Kowalchyk, J. A.; Yoon, E. J.; Preininger, A. M.; Alford, S.; Hamm, H. E.; Martin, T. F. G protein betagamma directly regulates SNARE protein fusion machinery for secretory granule exocytosis. Nat. Neurosci., 2005, 8 (4), 421-425.
56. Gerachshenko, T.; Blackmer, T.; Yoon, E. J.; Bartleson, C.; Hamm, H. E.; Alford, S. Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition. Nat. Neurosci., 2005, 8 (5), 597-605.
57. Delaney, A. J.; Crane, J. W.; Sah, P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron, 2007, 56 (5), 880-892.
58. Bashir, Z. I.; Jane, D. E.; Sunter, D. C.; Watkins, J. C.; Collingridge, G. L. Metabotropic glutamate receptors contribute to the induction of long-term depression in the CA1 region of the hippocampus. Eur. J. Pharmacol., 1993, 239 (1-3), 265-266.
59. Bolshakov, V. Y.; Siegelbaum, S. A. Postsynaptic induction and presynaptic expression of hippocampal long-term depression. Science, 1994, 264 (5162), 1148-1152.
60. Fitzjohn, S. M.; Kingston, A. E.; Lodge, D.; Collingridge, G. L. DHPG-induced LTD in area CA1 of juvenile rat hippocampus; characterisation and sensitivity to novel mGlu receptor antagonists. Neuropharmacology, 1999, 38 (10), 1577-1583.
61. Kemp, N.; Bashir, Z. I. Induction of LTD in the adult hippocampus by the synaptic activation of AMPA/kainate and metabotropic glutamate receptors. Neuropharmacology, 1999, 38 (4), 495-504.
62. O'Mara, S. M.; Rowan, M. J.; Anwyl, R. Metabotropic glutamate receptor-induced homosynaptic long-term depression and depotentiation in the dentate gyrus of the rat hippocampus in vitro. Neuropharmacology, 1995, 34 (8), 983-989.
63. Palmer, M. J.; Irving, A. J.; Seabrook, G. R.; Jane, D. E.; Collingridge, G. L. The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology, 1997, 36 (11-12), 1517-1532.
64. Wang, W.; Zhang, Z.; Shang, J.; Jiang, Z. Z.; Wang, S.; Liu, Y.; Zhang, L. Y. Activation of group I metabotropic glutamate receptors induces long-term depression in the hippocampal CA1 region of adult rats in vitro. Neurosci. Res., 2008, 62 (1), 43-50.
65. Gubellini, P.; Saulle, E.; Centonze, D.; Bonsi, P.; Pisani, A.; Bernardi, G.; Conquet, F.; Calabresi, P. Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology, 2001, 40 (7), 839-846.
66. Malenka, R. C.; Bear, M. F. LTP and LTD: an embarrassment of riches. Neuron, 2004, 44 (1), 5-21.
67. Kobayashi, K.; Manabe, T.; Takahashi, T. Presynaptic long-term depression at the hippocampal mossy fiber-CA3 synapse. Science, 1996, 273 (5275), 648-650.
68. Yokoi, M.; Kobayashi, K.; Manabe, T.; Takahashi, T.; Sakaguchi, I.; Katsuura, G.; Shigemoto, R.; Ohishi, H.; Nomura, S.; Nakamura, K.; Nakao, K.; Katsuki, M.; Nakanishi, S. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science, 1996, 273 (5275), 645-647.
69. Chen, Y. L.; Huang, C. C.; Hsu, K. S. Time-dependent reversal of long-term potentiation by low-frequency stimulation at the hippocampal mossy fiber-CA3 synapses. J. Neurosci., 2001, 21 (11), 3705-3714.
70. Hong, I.; Song, B.; Lee, S.; Kim, J.; Kim, J.; Choi, S. Extinction of cued fear memory involves a distinct form of depotentiation at cortical input synapses onto the lateral amygdala. Eur. J. Neurosci., 2009, 30 (11), 2089-2099.
71. Laezza, F.; Doherty, J. J.; Dingledine, R. Long-term depression in hippocampal interneurons: joint requirement for pre- and postsynaptic events. Science, 1999, 285 (5432), 1411-1414.
72. Gladding, C. M.; Fitzjohn, S. M.; Molnar, E. Metabotropic glutamate receptor-mediated long-term depression: molecular mechanisms. Pharmacol. Rev., 2009, 61 (4), 395-412.
73. Anwyl, R. Metabotropic glutamate receptor-dependent long-term potentiation. Neuropharmacology, 2009, 56 (4), 735-740.
74. Bashir, Z. I.; Bortolotto, Z. A.; Davies, C. H.; Berretta, N.; Irving, A. J.; Seal, A. J.; Henley, J. M.; Jane, D. E.; Watkins, J. C.; Collingridge, G. L. Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature, 1993, 363 (6427), 347-350.
75. Gubellini, P.; Saulle, E.; Centonze, D.; Costa, C.; Tropepi, D.; Bernardi, G.; Conquet, F.; Calabresi, P. Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology, 2003, 44 (1), 8-16.
76. Rebola, N.; Lujan, R.; Cunha, R. A.; Mulle, C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron, 2008, 57 (1), 121-134.
77. Kwon, H. B.; Castillo, P. E. Long-term potentiation selectively expressed by NMDA receptors at hippocampal mossy fiber synapses. Neuron, 2008, 57 (1), 108-120.
78. Bortolotto, Z. A.; Collett, V. J.; Conquet, F.; Jia, Z.; van der Putten, H.; Collingridge, G. L. The regulation of hippocampal LTP by the molecular switch, a form of metaplasticity, requires mGlu5 receptors. Neuropharmacology, 2005, 49 Suppl 1, 13-25.
79. Lu, Y. M.; Jia, Z.; Janus, C.; Henderson, J. T.; Gerlai, R.; Wojtowicz, J. M.; Roder, J. C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci., 1997, 17 (13), 5196-5205.
80. Naie, K.; Manahan-Vaughan, D. Regulation by metabotropic glutamate receptor 5 of LTP in the dentate gyrus of freely moving rats: relevance for learning and memory formation. Cereb. Cortex, 2004, 14 (2), 189-198.
81. Conquet, F.; Bashir, Z. I.; Davies, C. H.; Daniel, H.; Ferraguti, F.; Bordi, F.; Franz-Bacon, K.; Reggiani, A.; Matarese, V.; Conde, F. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature, 1994, 372 (6503), 237-243.
82. Little, Z.; Grover, L. M.; Teyler, T. J. Metabotropic glutamate receptor antagonist, (R,S)-alpha-methyl-4-carboxyphenyglycine, blocks two distinct forms of long-term potentiation in area CA1 of rat hippocampus. Neurosci. Lett., 1995, 201 (1), 73-76.
83. Wang, Y.; Rowan, M. J.; Anwyl, R. LTP induction dependent on activation of Ni2+-sensitive voltage-gated calcium channels, but not NMDA receptors, in the rat dentate gyrus in vitro. J. Neurophysiol., 1997, 78 (5), 2574-2581.
84. Lante, F.; de Jesus Ferreira, M. C.; Guiramand, J.; Recasens, M.; Vignes, M. Low-frequency stimulation induces a new form of LTP, metabotropic glutamate (mGlu5) receptor- and PKA-dependent, in the CA1 area of the rat hippocampus. Hippocampus, 2006, 16 (4), 345-360.
85. Liang, Y. C.; Huang, C. C.; Hsu, K. S. Characterization of longterm potentiation of primary afferent transmission at trigeminal synapses of juvenile rats: essential role of subtype 5 metabotropic glutamate receptors. Pain, 2005, 114 (3), 417-428.
86. Piccinin, S.; Thuault, S. J.; Doherty, A. J.; Brown, J. T.; Randall, A. D.; Davies, C. H.; Bortolotto, Z. A.; Collingridge, G. L. The induction of long-term plasticity of non-synaptic, synchronized activity by the activation of group I mGluRs. Neuropharmacology, 2008, 55 (4), 459-463.
87. Grover, L. M.; Yan, C. Evidence for involvement of group II/III metabotropic glutamate receptors in NMDA receptor-independent long-term potentiation in area CA1 of rat hippocampus. J. Neurophysiol., 1999, 82 (6), 2956-2969.
88. Rush, A. M.; Wu, J.; Rowan, M. J.; Anwyl, R. Group I metabotropic glutamate receptor (mGluR)-dependent long-term depression mediated via p38 mitogen-activated protein kinase is inhibited by previous high-frequency stimulation and activation of mGluRs and protein kinase C in the rat dentate gyrus in vitro. J. Neurosci., 2002, 22 (14), 6121-6128.
89. Mueser, K. T.; McGurk, S. R. Schizophrenia. Lancet, 2004, 363 (9426), 2063-2072.
90. Gray, J. A.; Roth, B. L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry, 2007, 12 (10), 904-922.
91. Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1 (2), 133-152.
92. Reynolds, G. P. Receptor mechanisms in the treatment of schizophrenia. J. Psychopharmacol., 2004, 18 (3), 340-345.
93. Lewis, D. A.; Moghaddam, B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol., 2006, 63 (10), 1372-1376.
94. Gaspar, P. A.; Bustamante, M. L.; Silva, H.; Aboitiz, F. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J. Neurochem., 2009, 111 (4), 891-900.
95. Krystal, J. H.; Karper, L. P.; Seibyl, J. P.; Freeman, G. K.; Delaney, R.; Bremner, J. D.; Heninger, G. R.; Bowers, M. B., Jr.; Charney, D. S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry, 1994, 51 (3), 199-214.
96. Lahti, A. C.; Weiler, M. A.; Tamara Michaelidis, B. A.; Parwani, A.; Tamminga, C. A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology, 2001, 25 (4), 455-467.
97. Gupta, D. S.; McCullumsmith, R. E.; Beneyto, M.; Haroutunian, V.; Davis, K. L.; Meador-Woodruff, J. H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse, 2005, 57 (3), 123-131.
98. Brody, S. A.; Conquet, F.; Geyer, M. A. Disruption of prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci., 2003, 18 (12), 3361-3366.
99. Pietraszek, M.; Gravius, A.; Schafer, D.; Weil, T.; Trifanova, D.; Danysz, W. mGluR5, but not mGluR1, antagonist modifies MK- 801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology, 2005, 49 (1), 73-85.
100. Attucci, S.; Carla, V.; Mannaioni, G.; Moroni, F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br. J. Pharmacol., 2001, 132 (4), 799-806.
101. Gray, L.; van den, B. M.; Scarr, E.; Dean, B.; Hannan, A. J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol., 2009, 12 (1), 45-60.
102. Homayoun, H.; Stefani, M. R.; Adams, B. W.; Tamagan, G. D.; Moghaddam, B. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology, 2004, 29 (7), 1259-1269.
103. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem., 2004, 47 (24), 5825-5828.
104. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P. J.; Popiolek, M.; Wantuch, C.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Lai, M.; Pruthi, F.; Pulicicchio, C.; Day, M.; Gilbert, A.; Pausch, M. H.; Brandon, N. J.; Beyer, C. E.; Comery, T. A.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K. L. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]- oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther., 2008, 327 (3), 827-839.
105. Diaz-Cabiale, Z.; Vivo, M.; Del, A. A.; O'Connor, W. T.; Harte, M. K.; Muller, C. E.; Martinez, E.; Popoli, P.; Fuxe, K.; Ferre, S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett., 2002, 324 (2), 154-158.
106. Darrah, J. M.; Stefani, M. R.; Moghaddam, B. Interaction of Nmethyl- D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav. Pharmacol., 2008, 19 (3), 225-234.
107. Homayoun, H.; Moghaddam, B. Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb. Cortex, 2006, 16 (1), 93-105.
108. Lecourtier, L.; Homayoun, H.; Tamagnan, G.; Moghaddam, B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonistinduced alteration of neuronal firing in prefrontal cortex. Biol. Psychiatry 2007, 62 (7), 739-746.
109. Koros, E.; Rosenbrock, H.; Birk, G.; Weiss, C.; Sams-Dodd, F. The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology, 2007, 32 (3), 562-576.
110. Devon, R. S.; Anderson, S.; Teague, P. W.; Muir, W. J.; Murray, V.; Pelosi, A. J.; Blackwood, D. H.; Porteous, D. J. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol. Psychiatry, 2001, 6 (3), 311-314.
111. Ohnuma, T.; Augood, S. J.; Arai, H.; McKenna, P. J.; Emson, P. C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain. Res. Mol. Brain. Res., 1998, 56 (1-2), 207-217.
112. Battaglia, G.; Monn, J. A.; Schoepp, D. D. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett., 1997, 229 (3), 161-164.
113. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med., 2007, 13 (9), 1102-1107.
114. Moghaddam, B.; Adams, B. W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 1998, 281 (5381), 1349-1352.
115. Rorick-Kehn, L. M.; Johnson, B. G.; Knitowski, K. M.; Salhoff, C. R.; Witkin, J. M.; Perry, K. W.; Griffey, K. I.; Tizzano, J. P.; Monn, J. A.; McKinzie, D. L.; Schoepp, D. D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl.,) 2007, 193 (1), 121-136.
116. Pinkerton, A. B.; Cube, R. V.; Hutchinson, J. H.; James, J. K.; Gardner, M. F.; Rowe, B. A.; Schaffhauser, H.; Rodriguez, D. E.; Campbell, U. C.; Daggett, L. P.; Vernier, J. M. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg. Med. Chem. Lett., 2005, 15 (6), 1565-1571.
117. Govek, S. P.; Bonnefous, C.; Hutchinson, J. H.; Kamenecka, T.; McQuiston, J.; Pracitto, R.; Zhao, L. X.; Gardner, M. F.; James, J. K.; Daggett, L. P.; Rowe, B. A.; Schaffhauser, H.; Bristow, L. J.; Campbell, U. C.; Rodriguez, D. E.; Vernier, J. M. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Bioorg. Med. Chem. Lett., 2005, 15 (18), 4068-4072.
118. Galici, R.; Jones, C. K.; Hemstapat, K.; Nong, Y.; Echemendia, N. G.; Williams, L. C.; de, P. T.; Conn, P. J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther., 2006, 318 (1), 173-185.
119. Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2- sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther., 2008, 326 (1), 209-217.
120. Woolley, M. L.; Pemberton, D. J.; Bate, S.; Corti, C.; Jones, D. N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl.,) 2008, 196 (3), 431-440.
121. Harich, S.; Gross, G.; Bespalov, A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl.,) 2007, 192 (4), 511-519.
122. Schlumberger, C.; Schafer, D.; Barberi, C.; More, L.; Nagel, J.; Pietraszek, M.; Schmidt, W. J.; Danysz, W. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav. Pharmacol., 2009, 20 (1), 56-66.
123. Homayoun, H.; Jackson, M. E.; Moghaddam, B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J. Neurophysiol., 2005, 93 (4), 1989-2001.
124. Krystal, J. H.; bi-Saab, W.; Perry, E.; D'Souza, D. C.; Liu, N.; Gueorguieva, R.; McDougall, L.; Hunsberger, T.; Belger, A.; Levine, L.; Breier, A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl), 2005, 179 (1), 303-309.
125. Ghose, S.; Crook, J. M.; Bartus, C. L.; Sherman, T. G.; Herman, M. M.; Hyde, T. M.; Kleinman, J. E.; Akil, M. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int. J. Neurosci., 2008, 118 (11), 1609-1627.
126. Ohtsuki, T.; Koga, M.; Ishiguro, H.; Horiuchi, Y.; Arai, M.; Niizato, K.; Itokawa, M.; Inada, T.; Iwata, N.; Iritani, S.; Ozaki, N.; Kunugi, H.; Ujike, H.; Watanabe, Y.; Someya, T.; Arinami, T. A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr. Res., 2008, 101 (1-3), 9-16.
127. Shibata, H.; Tani, A.; Chikuhara, T.; Kikuta, R.; Sakai, M.; Ninomiya, H.; Tashiro, N.; Iwata, N.; Ozaki, N.; Fukumaki, Y. Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res., 2009, 167 (1-2), 88-96.
128. Dev, K. K.; Henley, J. M. The schizophrenic faces of PICK1. Trends Pharmacol. Sci., 2006, 27 (11), 574-579.
129. de Rover, M.; Meye, F. J.; Ramakers, G. M. Presynaptic metabotropic glutamate receptors regulate glutamatergic input to dopamine neurons in the ventral tegmental area. Neuroscience, 2008, 154 (4), 1318-1323.
130. Li, X.; Gardner, E. L.; Xi, Z. X. The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats. Neuropharmacology, 2008, 54 (3), 542-551.
131. Li, X.; Li, J.; Peng, X. Q.; Spiller, K.; Gardner, E. L.; Xi, Z. X. Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: involvement of a ventral pallidal GABAergic mechanism. Neuropsychopharmacology, 2009, 34 (7), 1783-1796.
132. Callaerts-Vegh, Z.; Beckers, T.; Ball, S. M.; Baeyens, F.; Callaerts, P. F.; Cryan, J. F.; Molnar, E.; D'Hooge, R. Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7- deficient mice. J. Neurosci., 2006, 26 (24), 6573-6582.
133. Hölscher, C.; Schmid, S.; Pilz, P. K.; Sansig, G.; van der Putten, H.; Plappert, C. F. Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory. Behav. Brain Res., 2004, 154 (2), 473-481.
134. Hölscher, C.; Schmid, S.; Pilz, P. K.; Sansig, G.; van der Putten, H.; Plappert, C. F. Lack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memory. Learn. Mem., 2005, 12 (5), 450-455.
135. Bushell, T. J.; Sansig, G.; Collett, V. J.; van der, P. H.; Collingridge, G. L. Altered short-term synaptic plasticity in mice lacking the metabotropic glutamate receptor mGlu7. Sci. World J., 2002, 2, 730-737.
136. Takaki, H.; Kikuta, R.; Shibata, H.; Ninomiya, H.; Tashiro, N.; Fukumaki, Y. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am. J. Med. Genet B. Neuropsychiatr. Genet., 2004, 128B (1), 6-14.
137. Robbins, M. J.; Starr, K. R.; Honey, A.; Soffin, E. M.; Rourke, C.; Jones, G. A.; Kelly, F. M.; Strum, J.; Melarange, R. A.; Harris, A. J.; Rocheville, M.; Rupniak, T.; Murdock, P. R.; Jones, D. N.; Kew, J. N.; Maycox, P. R. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res., 2007, 1152, 215-227.
138. Baker, D. A.; Shen, H.; Kalivas, P. W. Cystine/glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration. Amino Acids, 2002, 23 (1-3), 161-162.
139. Moran, M. M.; McFarland, K.; Melendez, R. I.; Kalivas, P. W.; Seamans, J. K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J. Neurosci., 2005, 25 (27), 6389-6393.
140. Milton, A. L.; Lee, J. L.; Butler, V. J.; Gardner, R.; Everitt, B. J. Intra-amygdala and systemic antagonism of NMDA receptors prevents the reconsolidation of drug-associated memory and impairs subsequently both novel and previously acquired drug-seeking behaviors. J. Neurosci., 2008, 28 (33), 8230-8237.
141. Zweifel, L. S.; Argilli, E.; Bonci, A.; Palmiter, R. D. Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron, 2008, 59 (3), 486-496.
142. Lominac, K. D.; Kapasova, Z.; Hannun, R. A.; Patterson, C.; Middaugh, L. D.; Szumlinski, K. K. Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties. Drug Alcohol Depend., 2006, 85 (2), 142-156.
143. Dravolina, O. A.; Danysz, W.; Bespalov, A. Y. Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats. Psychopharmacology (Berl.,) 2006, 187 (4), 397-404.
144. Kotlinska, J.; Bochenski, M. Pretreatment with Group I metabotropic glutamate receptors antagonists attenuates lethality induced by acute cocaine overdose and expression of sensitization to hyperlocomotor effect of cocaine in mice. Neurotox. Res., 2009, 19 (1), 23-30.
145. Xie, X.; Ramirez, D. R.; Lasseter, H. C.; Fuchs, R. A. Effects of mGluR1 antagonism in the dorsal hippocampus on drug contextinduced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology (Berl.,) 2010, 208 (1), 1-11.
146. Dravolina, O. A.; Zakharova, E. S.; Shekunova, E. V.; Zvartau, E. E.; Danysz, W.; Bespalov, A. Y. mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology, 2007, 52 (2), 263-269.
147. Kotlinska, J.; Bochenski, M. Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice. Eur. J. Pharmacol., 2007, 558 (1-3), 113-118.
148. Blednov, Y. A.; Adron, H. R. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int. J. Neuropsychopharmacol., 2008, 11 (6), 775-793.
149. Schroeder, J. P.; Spanos, M.; Stevenson, J. R.; Besheer, J.; Salling, M.; Hodge, C. W. Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK1/2 phosphorylation in specific limbic brain regions: blockade by the mGluR5 antagonist MPEP. Neuropharmacology, 2008, 55 (4), 546-554.
150. Tessari, M.; Pilla, M.; Andreoli, M.; Hutcheson, D. M.; Heidbreder, C. A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotinetriggered relapse to nicotine-seeking. Eur. J. Pharmacol., 2004, 499 (1-2), 121-133.
151. Lee, B.; Platt, D. M.; Rowlett, J. K.; Adewale, A. S.; Spealman, R. D. Attenuation of behavioral effects of cocaine by the Metabotropic Glutamate Receptor 5 Antagonist 2-Methyl-6-(phenylethynyl)- pyridine in squirrel monkeys: comparison with dizocilpine. J. Pharmacol. Exp. Ther., 2005, 312 (3), 1232-1240.
152. Platt, D. M.; Rowlett, J. K.; Spealman, R. D. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology (Berl), 2008, 200 (2), 167-176.
153. Lea, P. M.; Faden, A. I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev., 2006, 12 (2), 149-166.
154. Pisani, A.; Bonsi, P.; Centonze, D.; Bernardi, G.; Calabresi, P. Functional coexpression of excitatory mGluR1 and mGluR5 on striatal cholinergic interneurons. Neuropharmacology, 2001, 40 (3), 460-463.
155. Gass, J. T.; Osborne, M. P.; Watson, N. L.; Brown, J. L.; Olive, M. F. mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology, 2009, 34 (4), 820-833.
156. Palucha, A.; Tatarczynska, E.; Branski, P.; Szewczyk, B.; Wieronska, J. M.; Klak, K.; Chojnacka-Wojcik, E.; Nowak, G.; Pilc, A. Group III mGlu receptor agonists produce anxiolytic- and antidepressant- like effects after central administration in rats. Neuropharmacology, 2004, 46 (2), 151-159.
157. Klodzinska, A.; Chojnacka-Wojcik, E.; Palucha, A.; Branski, P.; Popik, P.; Pilc, A. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology, 1999, 38 (12), 1831-1839.
158. Bäckström, P.; Hyytiä, P. Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)- 3,4-DCPG. Eur. J. Pharmacol., 2005, 528 (1-3), 110-118.
159. Peters, J.; Kalivas, P. W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and foodseeking behavior in rats. Psychopharmacology (Berl), 2006, 186 (2), 143-149.
160. Baptista, M. A.; Martin-Fardon, R.; Weiss, F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J. Neurosci., 2004, 24 (20), 4723-4727.
161. Bossert, J. M.; Gray, S. M.; Lu, L.; Shaham, Y. Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology, 2006, 31 (10), 2197-2209.
162. Liechti, M. E.; Lhuillier, L.; Kaupmann, K.; Markou, A. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J. Neurosci., 2007, 27 (34), 9077-9085.
163. Zhao, Y.; Dayas, C. V.; Aujla, H.; Baptista, M. A.; Martin-Fardon, R.; Weiss, F. Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J. Neurosci., 2006, 26 (39), 9967-9974.
164. Bossert, J. M.; Liu, S. Y.; Lu, L.; Shaham, Y. A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking. J. Neurosci., 2004, 24 (47), 10726-10730.
165. Vadasz, C.; Saito, M.; Gyetvai, B. M.; Oros, M.; Szakall, I.; Kovacs, K. M.; Prasad, V. V.; Toth, R. Glutamate receptor metabotropic 7 is cis-regulated in the mouse brain and modulates alcohol drinking. Genomics, 2007, 90 (6), 690-702.
166. Nielsen, D. A.; Ji, F.; Yuferov, V.; Ho, A.; Chen, A.; Levran, O.; Ott, J.; Kreek, M. J. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol. Psychiatry, 2008, 13 (4), 417-428.
167. Westenberg, H. G.; Sandner, C. Tolerability and safety of fluvoxamine and other antidepressants. Int. J. Clin. Pract., 2006, 60 (4), 482-491.
168. Cassano, P.; Fava, M. Tolerability issues during long-term treatment with antidepressants. Ann. Clin. Psychiatry, 2004, 16 (1), 15-25.
169. Baune, B. T.; Adrian, I.; Jacobi, F. Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. J. Psychosom. Res., 2007, 62 (2), 109-118.
170. Kessler, R. C.; Akiskal, H. S.; Ames, M.; Birnbaum, H.; Greenberg, P.; Hirschfeld, R. M.; Jin, R.; Merikangas, K. R.; Simon, G. E.; Wang, P. S. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry, 2006, 163 (9), 1561-1568.
171. Katz, M. M.; Maas, J. W.; Frazer, A.; Koslow, S. H.; Bowden, C. L.; Berman, N.; Swann, A. C.; Stokes, P. E. Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients. Neuropsychopharmacology, 1994, 11 (2), 89-100.
172. Bowden, C. L.; Koslow, S. H.; Hanin, I.; Maas, J. W.; Davis, J. M.; Robins, E. Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. Clin. Pharmacol. Ther., 1985, 37 (3), 316-324.
173. Akimova, E.; Lanzenberger, R.; Kasper, S. The serotonin-1A receptor in anxiety disorders. Biol. Psychiatry, 2009, 66 (7), 627-635.
174. Machado-Vieira, R.; Salvadore, G.; Luckenbaugh, D. A.; Manji, H. K.; Zarate, C. A., Jr. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J. Clin. Psychiatry, 2008, 69 (6), 946-958.
175. Henkel, V.; Seemuller, F.; Obermeier, M.; Adli, M.; Bauer, M.; Mundt, C.; Brieger, P.; Laux, G.; Bender, W.; Heuser, I.; Zeiler, J.; Gaebel, W.; Mayr, A.; Moller, H. J.; Riedel, M. Does early improvement triggered by antidepressants predict response/remission? - Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J. Affect. Disord., 2009, 115 (3), 439-449.
176. Millan, M. J. Dual- and Triple-Acting agents for treating core and Co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics, 2009, 6 (1), 53-77.
177. aan het Rot, M.; Collins, K. A.; Murrough, J. W.; Perez, A. M.; Reich, D. L.; Charney, D. S.; Mathew, S. J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry, 2010, 67 (2), 139-145.
178. Pilc, A.; Branski, P.; Palucha, A.; Tokarski, K.; Bijak, M. Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. Eur. J. Pharmacol., 1998, 349 (1), 83-87.
179. Bajkowska, M.; Branski, P.; Smialowska, M.; Pilc, A. Effect of chronic antidepressant or electroconvulsive shock treatment on mGLuR1a immunoreactivity expression in the rat hippocampus. Pol. J. Pharmacol., 1999, 51 (6), 539-541.
180. Smialowska, M.; Szewczyk, B.; Branski, P.; Wieronska, J. M.; Palucha, A.; Bajkowska, M.; Pilc, A. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology, 2002, 42 (8), 1016-1023.
181. Steckler, T.; Lavreysen, H.; Oliveira, A. M.; Aerts, N.; Van, C. H.; Prickaerts, J.; Megens, A.; Lesage, A. S. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology. (Berl.,) 2005, 179 (1), 198-206.
182. Mikulecka, A.; Mares, P. Effects of mGluR5 and mGluR1 antagonists on anxiety-like behavior and learning in developing rats. Behav. Brain Res., 2009, 204 (1), 133-139.
183. Ballard, T. M.; Woolley, M. L.; Prinssen, E.; Huwyler, J.; Porter, R.; Spooren, W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl), 2005, 179 (1), 218-229.
184. Spooren, W. P.; Vassout, A.; Neijt, H. C.; Kuhn, R.; Gasparini, F.; Roux, S.; Porsolt, R. D.; Gentsch, C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2- methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther., 2000, 295 (3), 1267-1275.
185. Spooren, W.; Gasparini, F. mGlu5 receptor antagonists: a novel class of anxiolytics? Drug News Perspect., 2004, 17 (4), 251-257.
186. Tatarczynska, E.; Klodzinska, A.; Chojnacka-Wojcik, E.; Palucha, A.; Gasparini, F.; Kuhn, R.; Pilc, A. Potential anxiolytic- and antidepressant- like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol., 2001, 132 (7), 1423-1430.
187. Spanka, C.; Glatthar, R.; Desrayaud, S.; Fendt, M.; Orain, D.; Troxler, T.; Vranesic, I. Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity. Bioorg. Med. Chem. Lett., 2010, 20 (1), 184-188.
188. Gravius, A.; Dekundy, A.; Nagel, J.; More, L.; Pietraszek, M.; Danysz, W. Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopainduced dyskinesia in rats. J. Neural. Transm., 2008, 115 (12), 1609-1619.
189. George, S. A.; Hutson, P. H.; Stephens, D. N. Differential effects of MPEP and diazepam in tests of conditioned emotional response and Pavlovian-to-instrumental transfer suggests 'anxiolytic' effects are mediated by different mechanisms. Psychopharmacology (Berl.,) 2009, 204 (3), 499-509.
190. Wieronska, J. M.; Branski, P.; Szewczyk, B.; Palucha, A.; Papp, M.; Gruca, P.; Moryl, E.; Pilc, A. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol. J. Pharmacol., 2001, 53 (6), 659-662.
191. Palucha, A.; Branski, P.; Szewczyk, B.; Wieronska, J. M.; Klak, K.; Pilc, A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol. Biochem. Behav., 2005, 81 (4), 901-906.
192. Belozertseva, I. V.; Kos, T.; Popik, P.; Danysz, W.; Bespalov, A. Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol., 2007, 17 (3), 172-179.
193. Li, X.; Need, A. B.; Baez, M.; Witkin, J. M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J. Pharmacol. Exp. Ther., 2006, 319 (1), 254-259.
194. Pilc, A.; Klodzinska, A.; Branski, P.; Nowak, G.; Palucha, A.; Szewczyk, B.; Tatarczynska, E.; Chojnacka-Wojcik, E.; Wieronska, J. M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology, 2002, 43 (2), 181-187.
195. Feyissa, A. M.; Woolverton, W. L.; Miguel-Hidalgo, J. J.; Wang, Z.; Kyle, P. B.; Hasler, G.; Stockmeier, C. A.; Iyo, A. H.; Karolewicz, B. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34 (2), 279-283.
196. Tsunoka, T.; Kishi, T.; Ikeda, M.; Kitajima, T.; Yamanouchi, Y.; Kinoshita, Y.; Kawashima, K.; Okochi, T.; Okumura, T.; Inada, T.; Ozaki, N.; Iwata, N. Association analysis of Group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33 (5), 875-879.
197. Egan, M. F.; Straub, R. E.; Goldberg, T. E.; Yakub, I.; Callicott, J. H.; Hariri, A. R.; Mattay, V. S.; Bertolino, A.; Hyde, T. M.; Shannon- Weickert, C.; Akil, M.; Crook, J.; Vakkalanka, R. K.; Balkissoon, R.; Gibbs, R. A.; Kleinman, J. E.; Weinberger, D. R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad Sci. USA, 2004, 101 (34), 12604-12609.
198. Wieronska, J. M.; Legutko, B.; Dudys, D.; Pilc, A. Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol. Rep., 2008, 60 (6), 844-855.
199. Matrisciano, F.; Caruso, A.; Orlando, R.; Marchiafava, M.; Bruno, V.; Battaglia, G.; Gruber, S. H.; Melchiorri, D.; Tatarelli, R.; Girardi, P.; Mathe, A. A.; Nicoletti, F. Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology, 2008, 55 (4), 525-531.
200. Matrisciano, F.; Storto, M.; Ngomba, R. T.; Cappuccio, I.; Caricasole, A.; Scaccianoce, S.; Riozzi, B.; Melchiorri, D.; Nicoletti, F. Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology, 2002, 42 (8), 1008-1015.
201. Kawashima, N.; Karasawa, J.; Shimazaki, T.; Chaki, S.; Okuyama, S.; Yasuhara, A.; Nakazato, A. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci. Lett., 2005, 378 (3), 131-134.
202. Karasawa, J.; Shimazaki, T.; Kawashima, N.; Chaki, S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res., 2005, 1042 (1), 92-98.
203. Yoshimizu, T.; Chaki, S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys. Res. Commun., 2004, 315 (2), 493-496.
204. Tanti, A.; Belzung, C. Open questions in current models of antidepressant action. Br. J. Pharmacol., 2010, 159 (6), 1187-1200.
205. Witkin, J. M.; Marek, G. J.; Johnson, B. G.; Schoepp, D. D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets, 2007, 6 (2), 87-100.
206. Chaki, S.; Yoshikawa, R.; Hirota, S.; Shimazaki, T.; Maeda, M.; Kawashima, N.; Yoshimizu, T.; Yasuhara, A.; Sakagami, K.; Okuyama, S.; Nakanishi, S.; Nakazato, A. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology, 2004, 46 (4), 457-467.
207. Cryan, J. F.; Valentino, R. J.; Lucki, I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev., 2005, 29 (4-5), 547-569.
208. Morishima, Y.; Miyakawa, T.; Furuyashiki, T.; Tanaka, Y.; Mizuma, H.; Nakanishi, S. Enhanced cocaine responsiveness and im paired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice. Proc. Natl. Acad Sci. USA, 2005, 102 (11), 4170-4175.
209. Matrisciano, F.; Scaccianoce, S.; Del, B. P.; Panaccione, I.; Canudas, A. M.; Battaglia, G.; Riozzi, B.; Ngomba, R. T.; Molinaro, G.; Tatarelli, R.; Melchiorri, D.; Nicoletti, F. Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramineinduced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J. Neurochem., 2005, 93 (5), 1345-1352.
210. Bespalov, A. Y.; van Gaalen, M. M.; Sukhotina, I. A.; Wicke, K.; Mezler, M.; Schoemaker, H.; Gross, G. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur. J. Pharmacol., 2008, 592 (1-3), 96-102.
211. Yoshimizu, T.; Shimazaki, T.; Ito, A.; Chaki, S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl.,) 2006, 186 (4), 587-593.
212. Wieronska, J. M.; Klak, K.; Palucha, A.; Branski, P.; Pilc, A. Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res., 2007, 1184, 88-95.
213. Tatarczynska, E.; Palucha, A.; Szewczyk, B.; Chojnacka-Wojcik, E.; Wieronska, J.; Pilc, A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1- aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol. J. Pharmacol., 2002, 54 (6), 707-710.
214. Klak, K.; Palucha, A.; Branski, P.; Sowa, M.; Pilc, A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant- like effects in rats. Amino Acids, 2007, 32 (2), 169-172.
215. Cryan, J. F.; Kelly, P. H.; Neijt, H. C.; Sansig, G.; Flor, P. J.; van der, P. H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci., 2003, 17 (11), 2409-2417.
216. Palucha, A.; Klak, K.; Branski, P.; van der, P. H.; Flor, P. J.; Pilc, A. Activation of the mGlu7 receptor elicits antidepressantlike effects in mice. Psychopharmacology (Berl), 2007, 194 (4), 555-562.
217. Stachowicz, K.; Klodzinska, A.; Palucha-Poniewiera, A.; Schann, S.; Neuville, P.; Pilc, A. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology, 2009, 57 (3), 227-234.
218. Fendt, M.; Burki, H.; Imobersteg, S.; van der, P. H.; McAllister, K.; Leslie, J. C.; Shaw, D.; Holscher, C. The effect of mGlu(8) deficiency in animal models of psychiatric diseases. Genes Brain Behav., 2010, 9 (1), 33-44.
219. Grillon, C. Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol. Psychiatry, 2002, 52 (10), 958-975.
220. de Lau, L. M.; Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol., 2006, 5 (6), 525-535.
221. Muangpaisan, W.; Hori, H.; Brayne, C. Systematic review of the prevalence and incidence of parkinson&rsquos disease in asia. J. Epidemiol., 2009, 19 (6), 281-293.
222. Albin, R. L.; Young, A. B.; Penney, J. B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci., 1995, 18 (2), 63-64.
223. Wichmann, T.; Delong, M. R. Anatomy and physiology of the basal ganglia: relevance to Parkinson's disease and related disorders. Handb. Clin. Neurol., 2007, 83, 1-18.
224. Bergman, H.; Wichmann, T.; Karmon, B.; Delong, M. R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol., 1994, 72 (2), 507-520.
225. Limousin, P.; Pollak, P.; Benazzouz, A.; Hoffmann, D.; Le Bas, J. F.; Broussolle, E.; Perret, J. E.; Benabid, A. L. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet, 1995, 345 (8942), 91-95.
226. Breit, S.; Bouali-Benazzouz, R.; Popa, R. C.; Gasser, T.; Benabid, A. L.; Benazzouz, A. Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp. Neurol., 2007, 205 (1), 36-47.
227. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models. Neuron, 2003, 39 (6), 889-909.
228. Rouse, S. T.; Marino, M. J.; Bradley, S. R.; Awad, H.; Wittmann, M.; Conn, P. J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther., 2000, 88 (3), 427-435.
229. Pisani, A.; Calabresi, P.; Centonze, D.; Bernardi, G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br. J. Pharmacol., 1997, 120 (6), 1007-1014.
230. Mao, L.; Wang, J. Q. Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P, and preproenkephalin mRNA expression in rat dorsal striatum. Synapse, 2001, 39 (1), 82-94.
231. Ossowska, K.; Wardas, J.; Pietraszek, M.; Konieczny, J.; Wolfarth, S. The striopallidal pathway is involved in antiparkinsonian-like effects of the blockade of group I metabotropic glutamate receptors in rats. Neurosci. Lett., 2003, 342 (1-2), 21-24.
232. Agari, T.; Yasuhara, T.; Matsui, T.; Kuramoto, S.; Kondo, A.; Miyoshi, Y.; Shingo, T.; Borlongan, C. V.; Date, I. Intrapallidal metabotropic glutamate receptor activation in a rat model of Parkinson's disease: Behavioral and histological analyses. Brain Research, 2008, 1203, 189-196.
233. Dekundy, A.; Pietraszek, M.; Schaefer, D.; Cenci, M. A.; Danysz, W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull., 2006, 69 (3), 318-326.
234. Breysse, N.; Baunez, C.; Spooren, W.; Gasparini, F.; Amalric, M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci., 2002, 22 (13), 5669-5678.
235. Breysse, N.; Amalric, M.; Salin, P. Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats. J. Neurosci., 2003, 23 (23), 8302-8309.
236. Pisani, A.; Gubellini, P.; Bonsi, P.; Conquet, F.; Picconi, B.; Centonze, D.; Bernardi, G.; Calabresi, P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl--aspartate responses in medium spiny striatal neurons. Neuroscience, 2001, 106 (3), 579-587.
237. Phillips, J. M.; Lam, H. A.; Ackerson, L. C.; Maidment, N. T. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci., 2006, 23 (1), 151-160.
238. Rylander, D.; Recchia, A.; Mela, F.; Dekundy, A.; Danysz, W.; Cenci, M. A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther., 2009, 330 (1), 227-235.
239. Mela, F.; Marti, M.; Dekundy, A.; Danysz, W.; Morari, M.; Cenci, M. A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem., 2007, 101 (2), 483-497.
240. Hill, M. P.; McGuire, S. G.; Crossman, A. R.; Brotchie, J. M. The mGlu5 receptor antagonist SIB-1830 reduces l-DOPA-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Abstr. Soc. Neurosci., 2001, 27, p.200.17.
241. Samadi, P.; Gregoire, L.; Morissette, M.; Calon, F.; Hadj, T. A.; Dridi, M.; Belanger, N.; Meltzer, L. T.; Bedard, P. J.; Di, P. T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging, 2008, 29 (7), 1040-1051.
242. Vernon, A. C.; Palmer, S.; Datla, K. P.; Zbarsky, V.; Croucher, M. J.; Dexter, D. T. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci., 2005, 22 (7), 1799-1806.
243. Vernon, A. C.; Zbarsky, V.; Datla, K. P.; Croucher, M. J.; Dexter, D. T. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J. Neurochem., 2007, 103 (3), 1075-1091.
244. Blandini, F.; Nappi, G.; Greenamyre, J. T. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann. Neurol., 2001, 49 (4), 525-529.
245. Piallat, B.; Benazzouz, A.; Benabid, A. L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur. J. Neurosci., 1996, 8 (7), 1408-1414.
246. Battaglia, G.; Busceti, C. L.; Molinaro, G.; Biagioni, F.; Storto, M.; Fornai, F.; Nicoletti, F.; Bruno, V. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine in mice. J. Neurosci., 2004, 24 (4), 828-835.
247. Samadi, P.; Rajput, A.; Calon, F.; Gregoire, L.; Hornykiewicz, O.; Rajput, A. H.; Di, P. T. Metabotropic glutamate receptor II in the brains of Parkinsonian patients. J. Neuropathol. Exp. Neurol., 2009, 68 (4), 374-382.
248. Dawson, L.; Chadha, A.; Megalou, M.; Duty, S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine- treated rat. Br. J. Pharmacol., 2000, 129 (3), 541-546.
249. Bradley, S. R.; Marino, M. J.; Wittmann, M.; Rouse, S. T.; Awad, H.; Levey, A. I.; Conn, P. J. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. J. Neurosci., 2000, 20 (9), 3085-3094.
250. Murray, T. K.; Messenger, M. J.; Ward, M. A.; Woodhouse, S.; Osborne, D. J.; Duty, S.; O'Neill, M. J. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav., 2002, 73 (2), 455-466.
251. Battaglia, G.; Busceti, C. L.; Pontarelli, F.; Biagioni, F.; Fornai, F.; Paparelli, A.; Bruno, V.; Ruggieri, S.; Nicoletti, F. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology, 2003, 45 (2), 155-166.
252. Wang, L.; Kitai, S. T.; Xiang, Z. Modulation of excitatory synaptic transmission by endogenous glutamate acting on presynaptic group II mGluRs in rat substantia nigra compacta. J. Neurosci. Res., 2005, 82 (6), 778-787.
253. Bradley, S. R.; Standaert, D. G.; Rhodes, K. J.; Rees, H. D.; Testa, C. M.; Levey, A. I.; Conn, P. J. Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. J. Comp. Neurol., 1999, 407 (1), 33-46.
254. Valenti, O.; Marino, M. J.; Wittmann, M.; Lis, E.; DiLella, A. G.; Kinney, G. G.; Conn, P. J. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci., 2003, 23 (18), 7218-7226.
255. Lopez, S.; Turle-Lorenzo, N.; Acher, F.; De, L. E.; Mele, A.; Amalric, M. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci., 2007, 27 (25), 6701-6711.
256. Marino, M. J.; Williams, D. L., Jr.; O'brien, J. A.; Valenti, O.; McDonald, T. P.; Clements, M. K.; Wang, R.; DiLella, A. G.; Hess, J. F.; Kinney, G. G.; Conn, P. J. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl. Acad Sci. USA, 2003, 100 (23), 13668-13673.
257. Beurrier, C.; Lopez, S.; Revy, D.; Selvam, C.; Goudet, C.; Lherondel, M.; Gubellini, P.; Kerkerian-LeGoff, L.; Acher, F.; Pin, J. P.; Amalric, M. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J., 2009, 23 (10), 3619-3628.
258. Jiang, Q.; Yan, Z.; Feng, J. Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism. J. Neurosci., 2006, 26 (16), 4318-4328.
259. Valenti, O.; Mannaioni, G.; Seabrook, G. R.; Conn, P. J.; Marino, M. J. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol. Exp. Ther., 2005, 313 (3), 1296-1304.
260. Greco, B.; Lopez, S.; Van der Putten, H. P.; Flor, P. J.; Amalric, M. Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J. Pharmacol. Exper. Therap., 2010, 332 (3), 1064-1071.
261. Hagerman, R. J.; Hagerman, P. J. The fragile X premutation: into the phenotypic fold. Curr. Opin. Genet Dev., 2002, 12 (3), 278-283.
262. Crawford, D. C.; Acuna, J. M.; Sherman, S. L. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med., 2001, 3 (5), 359-371.
263. Schütt, J.; Falley, K.; Richter, D.; Kreienkamp, H. J.; Kindler, S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J. Biol. Chem., 2009, 284 (38), 25479-25487.
264. Zukin, R. S.; Richter, J. D.; Bagni, C. Signals, synapses, and synthesis: how new proteins control plasticity. Front. Neural. Circuits, 2009, 3, 14.
265. The Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell, 1994, 78 (1), 23-33.
266. Kooy, R. F.; D'Hooge, R.; Reyniers, E.; Bakker, C. E.; Nagels, G.; De, B. K.; Storm, K.; Clincke, G.; De Deyn, P. P.; Oostra, B. A.; Willems, P. J. Transgenic mouse model for the fragile X syndrome. Am. J. Med. Genet., 1996, 64 (2), 241-245.
267. Yan, Q. J.; Rammal, M.; Tranfaglia, M.; Bauchwitz, R. P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology, 2005, 49 (7), 1053-1066.
268. Qin, M.; Kang, J.; Smith, C. B. A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience, 2005, 135 (3), 999-1009.
269. Qin, M.; Kang, J.; Smith, C. B. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc. Natl. Acad Sci. USA, 2002, 99 (24), 15758-15763.
270. Mineur, Y. S.; Huynh, L. X.; Crusio, W. E. Social behavior deficits in the Fmr1 mutant mouse. Behav. Brain Res., 2006, 168 (1), 172-175.
271. Spencer, C. M.; Alekseyenko, O.; Serysheva, E.; Yuva-Paylor, L. A.; Paylor, R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav., 2005, 4 (7), 420-430.
272. Irwin, S. A.; Patel, B.; Idupulapati, M.; Harris, J. B.; Crisostomo, R. A.; Larsen, B. P.; Kooy, F.; Willems, P. J.; Cras, P.; Kozlowski, P. B.; Swain, R. A.; Weiler, I. J.; Greenough, W. T. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet, 2001, 98 (2), 161-167.
273. Hinton, V. J.; Brown, W. T.; Wisniewski, K.; Rudelli, R. D. Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet, 1991, 41 (3), 289-294.
274. Rudelli, R. D.; Brown, W. T.; Wisniewski, K.; Jenkins, E. C.; Laure-Kamionowska, M.; Connell, F.; Wisniewski, H. M. Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol., 1985, 67 (3-4), 289-295.
275. Grossman, A. W.; Elisseou, N. M.; McKinney, B. C.; Greenough, W. T. Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines. Brain Res., 2006, 1084 (1), 158-164.
276. Galvez, R.; Greenough, W. T. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am. J. Med. Genet, A., 2005, 135 (2), 155-160.
277. Comery, T. A.; Harris, J. B.; Willems, P. J.; Oostra, B. A.; Irwin, S. A.; Weiler, I. J.; Greenough, W. T. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad Sci. USA, 1997, 94 (10), 5401-5404.
278. Bagni, C.; Greenough, W. T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat. Rev. Neurosci., 2005, 6 (5), 376-387.
279. Vaillend, C.; Poirier, R.; Laroche, S. Genes, plasticity and mental retardation. Behav. Brain Res., 2008, 192 (1), 88-105.
280. Bear, M. F.; Huber, K. M.; Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci., 2004, 27 (7), 370-377.
281. Huber, K. M.; Gallagher, S. M.; Warren, S. T.; Bear, M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad Sci. USA, 2002, 99 (11), 7746-7750.
282. Sharma, A.; Hoeffer, C. A.; Takayasu, Y.; Miyawaki, T.; McBride, S. M.; Klann, E.; Zukin, R. S. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci., 2010, 30 (2), 694-702.
283. Waung, M. W.; Huber, K. M. Protein translation in synaptic plasticity: mGluR-LTD, Fragile X. Curr. Opin. Neurobiol., 2009, 19 (3), 319-326.
284. Nosyreva, E. D.; Huber, K. M. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol., 2006, 95 (5), 3291-3295.
285. Dölen, G.; Osterweil, E.; Rao, B. S.; Smith, G. B.; Auerbach, B. D.; Chattarji, S.; Bear, M. F. Correction of fragile X syndrome in mice. Neuron, 2007, 56 (6), 955-962.
286. Yuskaitis, C. J.; Mines, M. A.; King, M. K.; Sweatt, J. D.; Miller, C. A.; Jope, R. S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol., 2010, 79 (4), 632-646.
287. McBride, S. M.; Choi, C. H.; Wang, Y.; Liebelt, D.; Braunstein, E.; Ferreiro, D.; Sehgal, A.; Siwicki, K. K.; Dockendorff, T. C.; Nguyen, H. T.; McDonald, T. V.; Jongens, T. A. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron, 2005, 45 (5), 753-764.
288. Choi, C. H.; McBride, S. M.; Schoenfeld, B. P.; Liebelt, D. A.; Ferreiro, D.; Ferrick, N. J.; Hinchey, P.; Kollaros, M.; Rudominer, R. L.; Terlizzi, A. M.; Koenigsberg, E.; Wang, Y.; Sumida, A.; Nguyen, H. T.; Bell, A. J.; McDonald, T. V.; Jongens, T. A. Age-dependent cognitive impairment in a Drosophila Fragile X model and its pharmacological rescue. Biogerontology, 2010, 11 (3), 347-362.
289. Tucker, B.; Richards, R. I.; Lardelli, M. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum. Mol. Genet., 2006, 15 (23), 3446-3458.
290. de Vrij, F. M.; Levenga, J.; van der Linde, H. C.; Koekkoek, S. K.; De Zeeuw, C. I.; Nelson, D. L.; Oostra, B. A.; Willemsen, R. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis., 2008, 31 (1), 127-132.
291. Berry-Kravis, E.; Hessl, D.; Coffey, S.; Hervey, C.; Schneider, A.; Yuhas, J.; Hutchison, J.; Snape, M.; Tranfaglia, M.; Nguyen, D. V.; Hagerman, R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet., 2009, 46 (4), 266-271.
292. Jacob, W.; Gravius, A.; Pietraszek, M.; Nagel, J.; Belozertseva, I.; Shekunova, E.; Malyshkin, A.; Greco, S.; Barberi, C.; Danysz, W. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology, 2009, 57 (2), 97-108.
293. Gravius, A.; Pietraszek, M.; Schafer, D.; Schmidt, W. J.; Danysz, W. Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning. Behav. Pharmacol., 2005, 16 (2), 113-121.
294. Bikbaev, A.; Neyman, S.; Ngomba, R. T.; Conn, P. J.; Nicoletti, F.; Manahan-Vaughan, D. MGluR5 mediates the interaction between late-LTP, network activity, and learning. PLoS One, 2008, 3 (5), e2155.
295. Hagerman, R. J.; Ono, M. Y.; Hagerman, P. J. Recent advances in fragile X: a model for autism and neurodegeneration. Curr. Opin. Psychiatry, 2005, 18 (5), 490-496.
296. Silverman, J. L.; Tolu, S. S.; Barkan, C. L.; Crawley, J. N. Repetitive Self-Grooming Behavior in the BTBR Mouse Model of Autism is Blocked by the mGluR5 Antagonist MPEP. Neuropsychopharmacology, 2010, 35 (4), 976-989.
297. Rego, A. C.; de Almeida, L. P. Molecular targets and therapeutic strategies in Huntington's disease. Curr. Drug Targets CNS Neurol. Disord., 2005, 4 (4), 361-381.
298. Li, S. H.; Li, X. J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet., 2004, 20 (3), 146-154.
299. Vonsattel, J. P.; DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol., 1998, 57 (5), 369-384.
300. Taylor-Robinson, S. D.; Weeks, R. A.; Bryant, D. J.; Sargentoni, J.; Marcus, C. D.; Harding, A. E.; Brooks, D. J. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. Disord., 1996, 11 (2), 167-173.
301. Fan, M. M.; Raymond, L. A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol., 2007, 81 (5-6), 272-293.
302. Bruno, V.; Ksiazek, I.; Battaglia, G.; Lukic, S.; Leonhardt, T.; Sauer, D.; Gasparini, F.; Kuhn, R.; Nicoletti, F.; Flor, P. J. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology, 2000, 39 (12), 2223-2230.
303. Anborgh, P. H.; Godin, C.; Pampillo, M.; Dhami, G. K.; Dale, L. B.; Cregan, S. P.; Truant, R.; Ferguson, S. S. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J. Biol. Chem., 2005, 280 (41), 34840-34848.
304. Ribeiro, F. M.; Paquet, M.; Ferreira, L. T.; Cregan, T.; Swan, P.; Cregan, S. P.; Ferguson, S. S. Metabotropic glutamate receptormediated cell signaling pathways are altered in a mouse model of Huntington's disease. J. Neurosci., 2010, 30 (1), 316-324.
305. Orlando, L. R.; Standaert, D. G.; Penney, J. B., Jr.; Young, A. B. Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3- hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions. Neurosci. Lett., 1995, 202 (1-2), 109-112.
306. Li, J. Y.; Popovic, N.; Brundin, P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. Neuro. Rx., 2005, 2 (3), 447-464.
307. Cha, J. H.; Kosinski, C. M.; Kerner, J. A.; Alsdorf, S. A.; Mangiarini, L.; Davies, S. W.; Penney, J. B.; Bates, G. P.; Young, A. B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad Sci. USA, 1998, 95 (11), 6480-6485.
308. Behrens, P. F.; Franz, P.; Woodman, B.; Lindenberg, K. S.; Landwehrmeyer, G. B. Impaired glutamate transport and glutamateglutamine cycling: downstream effects of the Huntington mutation. Brain, 2002, 125 (Pt 8), 1908-1922.
309. Schiefer, J.; Sprunken, A.; Puls, C.; Luesse, H. G.; Milkereit, A.; Milkereit, E.; Johann, V.; Kosinski, C. M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res., 2004, 1019 (1-2), 246-254.
310. Schiefer, J.; Landwehrmeyer, G. B.; Luesse, H. G.; Sprunken, A.; Puls, C.; Milkereit, A.; Milkereit, E.; Kosinski, C. M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord., 2002, 17 (4), 748-757.
311. Landwehrmeyer, G. B.; Dubois, B.; de Yebenes, J. G.; Kremer, B.; Gaus, W.; Kraus, P. H.; Przuntek, H.; Dib, M.; Doble, A.; Fischer, W.; Ludolph, A. C. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol., 2007, 62 (3), 262-272.
312. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12 (10), 383-388.
313. Francis, P. T. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2003, 18 (Suppl 1), S15-S21.
314. Bruno, V.; Battaglia, G.; Copani, A.; D'Onofrio, M.; Di, I. P.; De, B. A.; Melchiorri, D.; Flor, P. J.; Nicoletti, F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow. Metab., 2001, 21 (9), 1013-1033.
315. Albasanz, J. L.; Dalfo, E.; Ferrer, I.; Martin, M. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol. Dis., 2005, 20 (3), 685-693.
316. Lee, R. K.; Wurtman, R. J.; Cox, A. J.; Nitsch, R. M. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc. Natl. Acad Sci. USA, 1995, 92 (17), 8083-8087.
317. Jolly-Tornetta, C.; Gao, Z. Y.; Lee, V. M.; Wolf, B. A. Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons. J. Biol. Chem., 1998, 273 (22), 14015-14021.
318. Bruno, V.; Battaglia, G.; Ksiazek, I.; van der, P. H.; Catania, M. V.; Giuffrida, R.; Lukic, S.; Leonhardt, T.; Inderbitzin, W.; Gasparini, F.; Kuhn, R.; Hampson, D. R.; Nicoletti, F.; Flor, P. J. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci., 2000, 20 (17), 6413-6420.
319. Lee, H. G.; Zhu, X.; Casadesus, G.; Pallas, M.; Camins, A.; O'Neill, M. J.; Nakanishi, S.; Perry, G.; Smith, M. A. The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res., 2009, 1249, 244-250.
320. Bond, A.; Jones, N. M.; Hicks, C. A.; Whiffin, G. M.; Ward, M. A.; O'Neill, M. F.; Kingston, A. E.; Monn, J. A.; Ornstein, P. L.; Schoepp, D. D.; Lodge, D.; O'Neill, M. J. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther., 2000, 294 (3), 800-809.
321. Lee, H. G.; Ogawa, O.; Zhu, X.; O'Neill, M. J.; Petersen, R. B.; Castellani, R. J.; Ghanbari, H.; Perry, G.; Smith, M. A. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol., 2004, 107 (4), 365-371.
322. Neugebauer, V.; Lucke, T.; Schaible, H. G. Requirement of metabotropic glutamate receptors for the generation of inflammationevoked hyperexcitability in rat spinal cord neurons. Eur. J. Neurosci., 1994, 6 (7), 1179-1186.
323. Goudet, C.; Magnaghi, V.; Landry, M.; Nagy, F.; Gereau, R. W.; Pin, J. P. Metabotropic receptors for glutamate and GABA in pain. Brain Res. Rev., 2009, 60 (1), 43-56.
324. Lourenco, N. F.; Schadrack, J.; Berthele, A.; Zieglgansberger, W.; Tolle, T. R.; Castro-Lopes, J. M. Differential distribution of metabotropic glutamate receptor subtype mRNAs in the thalamus of the rat. Brain Res., 2000, 854 (1-2), 93-105.
325. Petralia, R. S.; Wang, Y. X.; Singh, S.; Wu, C.; Shi, L.; Wei, J.; Wenthold, R. J. A monoclonal antibody shows discrete cellular and subcellular localizations of mGluR1 alpha metabotropic glutamate receptors. J. Chem. Neuroanat., 1997, 13 (2), 77-93.
326. Neugebauer, V.; Li, W.; Bird, G. C.; Han, J. S. The amygdala and persistent pain. Neuroscientist, 2004, 10 (3), 221-234.
327. Neugebauer, V. The amygdala: different pains, different mechanisms. Pain 2007, 127 (1-2), 1-2.
328. Saab, C. Y.; Wang, J.; Gu, C.; Garner, K. N.; Al-Chaer, E. D. Microglia: a newly discovered role in visceral hypersensitivity? Neuron. Glia. Biol., 2007, 2 (4), 271-277.
329. Dolan, S.; Nolan, A. M. Behavioural evidence supporting a differential role for group I and II metabotropic glutamate receptors in spinal nociceptive transmission. Neuropharmacology, 2000, 39 (7), 1132-1138.
330. Fisher, K.; Coderre, T. J. The contribution of metabotropic glutamate receptors (mGluRs) to formalin-induced nociception. Pain, 1996, 68 (2-3), 255-263.
331. Fisher, K.; Fundytus, M. E.; Cahill, C. M.; Coderre, T. J. Intrathecal administration of the mGluR compound, (S)-4CPG, attenuates hyperalgesia and allodynia associated with sciatic nerve constriction injury in rats. Pain, 1998, 77 (1), 59-66.
332. Lorrain, D. S.; Correa, L.; Anderson, J.; Varney, M. Activation of spinal group I metabotropic glutamate receptors in rats evokes local glutamate release and spontaneous nociceptive behaviors: effects of 2-methyl-6-(phenylethynyl)-pyridine pretreatment. Neurosci. Lett., 2002, 327 (3), 198-202.
333. Fundytus, M. E.; Fisher, K.; Dray, A.; Henry, J. L.; Coderre, T. J. In vivo antinociceptive activity of anti-rat mGluR1 and mGluR5 antibodies in rats. Neuroreport, 1998, 9 (4), 731-735.
334. Fundytus, M. E.; Yashpal, K.; Chabot, J. G.; Osborne, M. G.; Lefebvre, C. D.; Dray, A.; Henry, J. L.; Coderre, T. J. Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats. Br. J. Pharmacol., 2001, 132 (1), 354-367.
335. Fundytus, M. E.; Osborne, M. G.; Henry, J. L.; Coderre, T. J.; Dray, A. Antisense oligonucleotide knockdown of mGluR1 alleviates hyperalgesia and allodynia associated with chronic inflammation. Pharmacol. Biochem. Behav., 2002, 73 (2), 401-410.
336. Noda, K.; Anzai, T.; Ogata, M.; Akita, H.; Ogura, T.; Saji, M. Antisense knockdown of spinal-mGluR1 reduces the sustained phase of formalin-induced nociceptive responses. Brain Res., 2003, 987 (2), 194-200.
337. Young, M. R.; Blackburn-Munro, G.; Dickinson, T.; Johnson, M. J.; Anderson, H.; Nakalembe, I.; Fleetwood-Walker, S. M. Antisense ablation of type I metabotropic glutamate receptor mGluR1 inhibits spinal nociceptive transmission. J. Neurosci., 1998, 18 (23), 10180-10188.
338. Adwanikar, H.; Karim, F.; Gereau, R. W. Inflammation persistently enhances nocifensive behaviors mediated by spinal group I mGluRs through sustained ERK activation. Pain, 2004, 111 (1-2), 125-135.
339. Salt, T. E.; Turner, J. P. Reduction of sensory and metabotropic glutamate receptor responses in the thalamus by the novel metabotropic glutamate receptor-1-selective antagonist S-2-methyl-4- carboxy-phenylglycine. Neuroscience, 1998, 85 (3), 655-658.
340. Han, J. S.; Neugebauer, V. mGluR1 and mGluR5 antagonists in the amygdala inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain. Pain, 2005, 113 (1-2), 211-222.
341. Kingston, A. E.; Griffey, K.; Johnson, M. P.; Chamberlain, M. J.; Kelly, G.; Tomlinson, R.; Wright, R. A.; Johnson, B. G.; Schoepp, D. D.; Harris, J. R.; Clark, B. P.; Baker, R. S.; Tizzano, J. T. Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists. Neurosci. Lett., 2002, 330 (2), 127-130.
342. Lavreysen, H.; Janssen, C.; Bischoff, F.; Langlois, X.; Leysen, J. E.; Lesage, A. S. [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol. Pharmacol., 2003, 63 (5), 1082-1093.
343. Varty, G. B.; Grilli, M.; Forlani, A.; Fredduzzi, S.; Grzelak, M. E.; Guthrie, D. H.; Hodgson, R. A.; Lu, S. X.; Nicolussi, E.; Pond, A. J.; Parker, E. M.; Hunter, J. C.; Higgins, G. A.; Reggiani, A.; Bertorelli, R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl), 2005, 179 (1), 207-217.
344. Zhang, L.; Lu, Y.; Chen, Y.; Westlund, K. N. Group I metabotropic glutamate receptor antagonists block secondary thermal hyperalgesia in rats with knee joint inflammation. J. Pharmacol. Exp. Ther., 2002, 300 (1), 149-156.
345. Salt, T. E.; Turner, J. P.; Kingston, A. E. Evaluation of agonists and antagonists acting at Group I metabotropic glutamate receptors in the thalamus in vivo. Neuropharmacology, 1999, 38 (10), 1505-1510.
346. Lee, K. S.; Kim, J.; Yoon, Y. W.; Lee, M. G.; Hong, S. K.; Han, H. C. The peripheral role of group I metabotropic glutamate receptors on nociceptive behaviors in rats with knee joint inflammation. Neurosci. Lett., 2007, 416 (2), 123-127.
347. El-Kouhen, O.; Lehto, S. G.; Pan, J. B.; Chang, R.; Baker, S. J.; Zhong, C.; Hollingsworth, P. R.; Mikusa, J. P.; Cronin, E. A.; Chu, K. L.; McGaraughty, S. P.; Uchic, M. E.; Miller, L. N.; Rodell, N. M.; Patel, M.; Bhatia, P.; Mezler, M.; Kolasa, T.; Zheng, G. Z.; Fox, G. B.; Stewart, A. O.; Decker, M. W.; Moreland, R. B.; Brioni, J. D.; Honore, P. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br. J. Pharmacol., 2006, 149 (6), 761-774.
348. Zheng, G. Z.; Bhatia, P.; Daanen, J.; Kolasa, T.; Patel, M.; Latshaw, S.; El Kouhen, O. F.; Chang, R.; Uchic, M. E.; Miller, L.; Nakane, M.; Lehto, S. G.; Honore, M. P.; Moreland, R. B.; Brioni, J. D.; Stewart, A. O. Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J. Med. Chem., 2005, 48 (23), 7374-7388.
349. Zhu, C. Z.; Baker, S.; Ei-Kouhen, O.; Lehto, S. G.; Hollingsworth, P. R.; Gauvin, D. M.; Hernandez, G.; Zheng, G.; Chang, R.; Moreland, R. B.; Stewart, A. O.; Brioni, J. D.; Honore, P. Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats. Eur. J. Pharmacol., 2008, 580 (3), 314-321.
350. Binns, K. E.; Salt, T. E. Actions of the systemically active metabotropic glutamate antagonist MPEP on sensory responses of thalamic neurones. Neuropharmacology, 2001, 40 (5), 639-644.
351. Dogrul, A.; Ossipov, M. H.; Lai, J.; Malan, T. P., Jr.; Porreca, F. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats. Neurosci. Lett., 2000, 292 (2), 115-118.
352. Zhu, C. Z.; Wilson, S. G.; Mikusa, J. P.; Wismer, C. T.; Gauvin, D. M.; Lynch, J. J., III; Wade, C. L.; Decker, M. W.; Honore, P. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur. J. Pharmacol., 2004, 506 (2), 107-118.
353. Palazzo, E.; Marabese, I.; de, N., V; Oliva, P.; Rossi, F.; Berrino, L.; Rossi, F.; Maione, S. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology, 2001, 40 (3), 319-326.
354. Wroblewska, B. NAAG as a neurotransmitter. Adv. Exp. Med. Biol., 2006, 576, 317-325.
355. Nagel, J.; Belozertseva, I.; Greco, S.; Kashkin, V.; Malyshkin, A.; Jirgensons, A.; Shekunova, E.; Eilbacher, B.; Bespalov, A.; Danysz, W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology, 2006, 51 (7-8), 1163-1171.
356. Yamamoto, T.; Hirasawa, S.; Wroblewska, B.; Grajkowska, E.; Zhou, J.; Kozikowski, A.; Wroblewski, J.; Neale, J. H. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur. J. Neurosci., 2004, 20 (2), 483-494.
357. Dolan, S.; Nolan, A. M. Behavioral evidence supporting a differential role for spinal group I and II metabotropic glutamate receptors in inflammatory hyperalgesia in sheep. Neuropharmacology, 2002, 43 (3), 319-326.
358. Li, W.; Neugebauer, V. Differential changes of group II and group III mGluR function in central amygdala neurons in a model of arthritic pain. J. Neurophysiol., 2006, 96 (4), 1803-1815.
359. Neugebauer, V.; Chen, P. S.; Willis, W. D. Groups II and III metabotropic glutamate receptors differentially modulate brief and prolonged nociception in primate STT cells. J. Neurophysiol., 2000, 84 (6), 2998-3009.
360. Sharpe, E. F.; Kingston, A. E.; Lodge, D.; Monn, J. A.; Headley, P. M. Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br. J. Pharmacol., 2002, 135 (5), 1255-1262.
361. Simmons, R. M.; Webster, A. A.; Kalra, A. B.; Iyengar, S. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol. Biochem. Behav., 2002, 73 (2), 419-427.
362. Varney, M. A.; Gereau, R. W. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr. Drug Targets CNS Neurol. Disord., 2002, 1 (3), 283-296.
363. Yang, D.; Gereau, R. W. Peripheral group II metabotropic glutamate receptors mediate endogenous anti-allodynia in inflammation. Pain, 2003, 106 (3), 411-417.
364. Neugebauer, V.; Carlton, S. M. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opin. Ther. Targets, 2002, 6 (3), 349-361.
365. Jones, C. K.; Eberle, E. L.; Peters, S. C.; Monn, J. A.; Shannon, H. E. Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. Neuropharmacology, 2005, 49 Suppl 1, 206-218.
366. Chen, S. R.; Pan, H. L. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J. Pharmacol. Exp. Ther., 2005, 312 (1), 120-126.
367. Goudet, C.; Chapuy, E.; Alloui, A.; Acher, F.; Pin, J. P.; Eschalier, A. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain, 2008, 137 (1), 112-124.
368. Han, J. S.; Bird, G. C.; Neugebauer, V. Enhanced group III mGluRmediated inhibition of pain-related synaptic plasticity in the amygdala. Neuropharmacology, 2004, 46 (7), 918-926.
369. Palazzo, E.; Fu, Y.; Ji, G.; Maione, S.; Neugebauer, V. Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors. Neuropharmacology, 2008, 55 (4), 537-545.
370. Bradford, H. F. Glutamate, GABA and epilepsy. Prog. Neurobiol., 1995, 47 (6), 477-511.
371. Chapman, A. G.; Elwes, R. D.; Millan, M. H.; Polkey, C. E.; Meldrum, B. S. Role of glutamate and aspartate in epileptogenesis; contribution of microdialysis studies in animal and man. Epilepsy, Res. Suppl., 1996, 12, 239-246.
372. Chapman, A. G. Glutamate and epilepsy. J. Nutr., 2000, 130 (4S Suppl), 1043S-1045S.
373. Chapman, A.; Meldrum, B. Excitatory amino acids in epilepsy and novel anti-epileptic drugs. Epilepsy Res. Suppl., 1991, 3, 39-48.
374. Meldrum, B. S. Excitatory amino acid transmitters in epilepsy. Epilepsia, 1991, 32 Suppl 2, S1-S3.
375. Meldrum, B. S. Excitatory amino acids in epilepsy and potential novel therapies. Epilepsy Res., 1992, 12 (2), 189-196.
376. Notenboom, R. G.; Hampson, D. R.; Jansen, G. H.; van Rijen, P. C.; van Veelen, C. W.; van, N. O.; de Graan, P. N. Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients. Brain, 2006, 129 (Pt 1), 96-107.
377. Aronica, E.; Gorter, J. A.; Jansen, G. H.; van Veelen, C. W.; van Rijen, P. C.; Ramkema, M.; Troost, D. Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia. Epilepsia, 2003, 44 (6), 785-795.
378. Chapman, A. G. Glutamate receptors in epilepsy. Prog. Brain Res., 1998, 116, 371-383.
379. Moldrich, R. X.; Beart, P. M. Emerging signalling and protein interactions mediated via metabotropic glutamate receptors. Curr. Drug Targets CNS Neurol. Disord., 2003, 2 (2), 109-122.
380. Tang, F. R. Agonists and antagonists of metabotropic glutamate receptors: anticonvulsants and antiepileptogenic agents? Curr. Neuropharmacol., 2005, 3 (4), 299-307.
381. Tizzano, J. P.; Griffey, K. I.; Johnson, J. A.; Fix, A. S.; Helton, D. R.; Schoepp, D. D. Intracerebral 1S,3R-1-aminocyclopentane-1,3- dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists. Neurosci. Lett., 1993, 162 (1-2), 12-16.
382. Thomsen, C.; Klitgaard, H.; Sheardown, M.; Jackson, H. C.; Eskesen, K.; Jacobsen, P.; Treppendahl, S.; Suzdak, P. D. (S)-4- carboxy-3-hydroxyphenylglycine, an antagonist of metabotropic glutamate receptor (mGluR) 1a and an agonist of mGluR2, protects against audiogenic seizures in DBA/2 mice. J. Neurochem., 1994, 62 (6), 2492-2495.
383. Dalby, N. O.; Thomsen, C. Modulation of seizure activity in mice by metabotropic glutamate receptor ligands. J. Pharmacol. Exp. Ther., 1996, 276 (2), 516-522.
384. Chapman, A. G.; Yip, P. K.; Yap, J. S.; Quinn, L. P.; Tang, E.; Harris, J. R.; Meldrum, B. S. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)- 1-aminoindan-1,5-dicarboxylic acid). Eur. J. Pharmacol., 1999, 368 (1), 17-24.
385. Burgess, D. L.; Jones, J. M.; Meisler, M. H.; Noebels, J. L. Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse. Cell, 1997, 88 (3), 385-392.
386. Nagaraja, R. Y.; Grecksch, G.; Reymann, K. G.; Schroeder, H.; Becker, A. Group I metabotropic glutamate receptors interfere in different ways with pentylenetetrazole seizures, kindling, and kindling- related learning deficits. Naunyn. Schmiedebergs. Arch. Pharmacol., 2004, 370 (1), 26-34.
387. Thomsen, C.; Dalby, N. O. Roles of metabotropic glutamate receptor subtypes in modulation of pentylenetetrazole-induced seizure activity in mice. Neuropharmacology, 1998, 37 (12), 1465-1473.
388. Smolders, I.; Lindekens, H.; Clinckers, R.; Meurs, A.; O'Neill, M. J.; Lodge, D.; Ebinger, G.; Michotte, Y. In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands. J. Neurochem., 2004, 88 (5), 1068-1077.
389. Renaud, J.; Emond, M.; Meilleur, S.; Psarropoulou, C.; Carmant, L. AIDA, a class I metabotropic glutamate-receptor antagonist limits kainate-induced hippocampal dysfunction. Epilepsia, 2002, 43 (11), 1306-1317.
390. Chapman, A. G.; Nanan, K.; Williams, M.; Meldrum, B. S. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)- pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology, 2000, 39 (9), 1567-1574.
391. Ermolinsky, B.; Pacheco Otalora, L. F.; Arshadmansab, M. F.; Zarei, M. M.; Garrido-Sanabria, E. R. Differential changes in mGlu2 and mGlu3 gene expression following pilocarpine-induced status epilepticus: a comparative real-time PCR analysis. Brain Res., 2008, 1226, 173-180.
392. Garrido-Sanabria, E. R.; Otalora, L. F.; Arshadmansab, M. F.; Herrera, B.; Francisco, S.; Ermolinsky, B. S. Impaired expression and function of group II metabotropic glutamate receptors in pilocarpine-treated chronically epileptic rats. Brain Res., 2008, 1240, 165-176.
393. Attwell, P. J.; Singh, K. N.; Jane, D. E.; Croucher, M. J.; Bradford, H. F. Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV). Brain Res., 1998, 805 (1-2), 138-143.
394. Tang, E.; Yip, P. K.; Chapman, A. G.; Jane, D. E.; Meldrum, B. S. Prolonged anticonvulsant action of glutamate metabotropic receptor agonists in inferior colliculus of genetically epilepsy-prone rats. Eur. J. Pharmacol., 1997, 327 (2-3), 109-115.
395. Miyamoto, M.; Ishida, M.; Shinozaki, H. Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group II metabotropic glutamate receptors against intraventricular kainate in the rat. Neuroscience, 1997, 77 (1), 131-140.
396. Moldrich, R. X.; Jeffrey, M.; Talebi, A.; Beart, P. M.; Chapman, A. G.; Meldrum, B. S. Anti-epileptic activity of group II metabotropic glutamate receptor agonists (--)-2-oxa-4-aminobicyclo[3.1.0] hexane-4,6-dicarboxylate (LY379268) and (--)-2-thia-4-aminobicyclo [3.1.0]hexane-4,6-dicarboxylate (LY389795). Neuropharmacology, 2001, 41 (1), 8-18.
397. Duvoisin, R. M.; Zhang, C.; Pfankuch, T. F.; O'Connor, H.; Gayet- Primo, J.; Quraishi, S.; Raber, J. Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. Eur. J. Neurosci., 2005, 22 (2), 425-436.
398. Sansig, G.; Bushell, T. J.; Clarke, V. R.; Rozov, A.; Burnashev, N.; Portet, C.; Gasparini, F.; Schmutz, M.; Klebs, K.; Shigemoto, R.; Flor, P. J.; Kuhn, R.; Knoepfel, T.; Schroeder, M.; Hampson, D. R.; Collett, V. J.; Zhang, C.; Duvoisin, R. M.; Collingridge, G. L.; van der, P. H. Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7. J. Neurosci., 2001, 21 (22), 8734-8745.
399. Kral, T.; Erdmann, E.; Sochivko, D.; Clusmann, H.; Schramm, J.; Dietrich, D. Down-regulation of mGluR8 in pilocarpine epileptic rats. Synapse, 2003, 47 (4), 278-284.
400. Chen, J.; Larionov, S.; Pitsch, J.; Hoerold, N.; Ullmann, C.; Elger, C. E.; Schramm, J.; Becker, A. J. Expression analysis of metabotropic glutamate receptors I and III in mouse strains with different susceptibility to experimental temporal lobe epilepsy. Neurosci. Lett., 2005, 375 (3), 192-197.
401. Ghauri, M.; Chapman, A. G.; Meldrum, B. S. Convulsant and anticonvulsant actions of agonists and antagonists of group III mGluRs. Neuroreport., 1996, 7 (9), 1469-1474.
402. Chapman, A. G.; Talebi, A.; Yip, P. K.; Meldrum, B. S. Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid. Eur. J. Pharmacol., 2001, 424 (2), 107-113.
403. Chapman, A. G.; Nanan, K.; Yip, P.; Meldrum, B. S. Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4-phosphonophenylglycine. Eur. J. Pharmacol., 1999, 383 (1), 23-27.
404. Gasparini, F.; Bruno, V.; Battaglia, G.; Lukic, S.; Leonhardt, T.; Inderbitzin, W.; Laurie, D.; Sommer, B.; Varney, M. A.; Hess, S. D.; Johnson, E. C.; Kuhn, R.; Urwyler, S.; Sauer, D.; Portet, C.; Schmutz, M.; Nicoletti, F.; Flor, P. J. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J. Pharmacol. Exp. Ther., 1999, 289 (3), 1678-1687.
405. Folbergrova, J.; Druga, R.; Haugvicova, R.; Mares, P.; Otahal, J. Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid. Neuropharmacology, 2008, 54 (4), 665-675.
406. Hosford, D. A.; Wang, Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia, 1997, 38 (4), 408-414.